Back to Search Start Over

High-dose chemotherapy for relapsed testicular germ cell tumours.

Authors :
Chovanec M
Adra N
Abu Zaid M
Abonour R
Einhorn L
Source :
Nature reviews. Urology [Nat Rev Urol] 2023 Apr; Vol. 20 (4), pp. 217-225. Date of Electronic Publication: 2022 Dec 07.
Publication Year :
2023

Abstract

Relapsed testicular germ cell tumours (GCTs) might be cured with salvage chemotherapy. Accepted salvage treatment is conventional-dose chemotherapy (CDCT) or high-dose chemotherapy (HDCT). HDCT with peripheral blood stem cell transplant might produce a higher number of durable responses than CDCT. We discuss studies reporting on outcomes of salvage HDCT in relapsed GCTs. The most reproducible results were achieved with HDCT with two cycles of etoposide and carboplatin or three cycles of the paclitaxel, ifosfamide, carboplatin and etoposide regime. Using these two regimens, sustained cure rates of 50-66% were reported in phase I, phase II and retrospective studies published in the past two decades. Cure rates in patients with cisplatin-resistant disease are between 30% and 45%. Two phase III randomized studies were conducted with certain limitations and were unsuccessful in showing a survival benefit of HDCT. Thus, salvage treatment remains a controversial topic. Salvage HDCT with peripheral blood stem cell transplant and CDCT are two recommended treatment options for relapsed GCTs. Consistently reported cure rates from phase I, phase II and large retrospective studies support the use of HDCT in the hands of an experienced team of oncologists.<br /> (© 2022. Springer Nature Limited.)

Details

Language :
English
ISSN :
1759-4820
Volume :
20
Issue :
4
Database :
MEDLINE
Journal :
Nature reviews. Urology
Publication Type :
Academic Journal
Accession number :
36477219
Full Text :
https://doi.org/10.1038/s41585-022-00683-1